Design Therapeutics Inc

In a Stage 2 advancing corrective reset within a broader uptrend, active Lockout Rally dynamics and sustained EMA support justify immediate bullish participation despite overbought readings, focusing on pullbacks into rising EMA confluence near the prior breakout zone.

• ↑Phase I data: 300 mg DT216 increased frataxin mRNA by 30%
• ↑$303 M cash supports operations through 2026, minimizing dilution risk
• ↓Negative profitability metrics undermine return prospects